bcl-2 is down-regulated in atypical endometrial hyperplasia and adenocarcinoma

被引:0
|
作者
Henderson, GS
Brown, KA
Perkins, SL
Abbott, TM
Clayton, F
机构
[1] UNIV UTAH, HLTH SCI CTR, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA
[2] VET ADM MED CTR, SALT LAKE CITY, UT 84148 USA
关键词
atypical hyperplasia; bcl-2; protein; endometrial carcinoma; immunohistochemistry; oncogene;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The bcl-2 protein, which protects cells from apoptosis, is normally expressed in a number of adult tissues. Dysregulated bcl-2 expression, secondary to (14;18) chromosomal translocation, seems to promote the development of follicular lymphomas, and recent findings of bcl-2 protein in several solid tumors suggest that it might contribute to the genesis of many other neoplasms, bcl-2 is also highly expressed in normal proliferative endometrium and markedly down-regulated in secretory endometrium, which suggests that its expression is estrogen regulated, Because the development of most endometrial carcinomas is associated with hyperestrogenic states, we began the investigation of the role of bcl-2 in endometrial carcinogenesis by immunohistochemically quantifying its expression in proliferative, hyperplastic, atypically hyperplastic, and carcinomatous endometrium. The results of this study show that bcl-2 is relatively highly expressed in proliferative (n = 11) and hyperplastic (n = 18) endometrium, with respective mean staining scores of 3.59 and 3.47 (scale, 0-4), but is significantly (P < 0.001) down-regulated in atypical hyperplasia (a = 11; score, 0.82), and adenocarcinoma (n = 34; score, 0.86), bcl-2 expression did not correlate with stage, grade, estrogen-receptor, or progesterone-receptor expression, Polymerase chain reaction analyses of DNA isolated from several endometrial carcinomas were negative for (14;18) translocation involving the bcl-2 gene. Thus, bcI-2 apparently plays no role in the progression of atypical hyperplasia to carcinoma or in the development of high-grade or advanced-stage endometrial carcinoma. These results, however, do not rule out the involvement of bcl-2 in very early, preatypical hyperplasia phases of endometrial carcinogenesis. Finally the marked difference in bcl-2 expression in hyperplastic and atypically hyperplastic glands might prove to be diagnostically useful in the often difficult distinction of these entities.
引用
收藏
页码:430 / 438
页数:9
相关论文
共 50 条
  • [1] BCL-2 EXPRESSION IS DOWN-REGULATED IN ATYPICAL ENDOMETRIAL HYPERPLASIA AND ADENOCARCINOMA
    HENDERSON, GS
    BROWN, K
    ABBOTT, T
    PERKINS, SL
    CLAYTON, F
    [J]. LABORATORY INVESTIGATION, 1995, 72 (01) : A90 - A90
  • [2] NUCLEAR AND CYTOPLASMIC BCL-2 EXPRESSION IN ENDOMETRIAL HYPERPLASIA AND ADENOCARCINOMA
    CHAN, WK
    MOLE, MM
    LEVISON, DA
    BALL, RY
    LU, QL
    PATEL, K
    HANBY, AM
    [J]. JOURNAL OF PATHOLOGY, 1995, 177 (03): : 241 - &
  • [3] BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib
    Li, Feng
    Pascal, Laura E.
    Zhou, Jianhua
    Zhou, Yibin
    Wang, Ke
    Parwani, Anil V.
    Dhir, Rajiv
    Guo, Peng
    He, Dalin
    Nelson, Joel B.
    Wang, Zhou
    [J]. AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2018, 6 (01): : 1 - 10
  • [4] The role of Bcl-2 in apoptotic process of non-atypical endometrial hyperplasia
    Cahyanti, R. D.
    Wijaya, I.
    Kristanto, H.
    [J]. 13TH WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY (COGI) HELD JOINTLY WITH THE GERMAN SOCIETY OF OBSTETRICS & GYNECOLOGY, 2010, : 227 - 231
  • [5] Aberrant bcl-2 deficiency in endometrial hyperplasia
    Jafari-Nejad, Kambin
    Orell, Svante
    Henshaw, Richard
    Tokushige, Natsuko
    Russell, Peter
    [J]. PATHOLOGY, 2011, 43 (04) : 378 - 380
  • [6] bcl-2 expression in endometrial hyperplasia and carcinoma
    Niemann, TH
    Trgovac, TL
    McGaughy, VR
    Vaccarello, L
    [J]. GYNECOLOGIC ONCOLOGY, 1996, 63 (03) : 318 - 322
  • [7] BCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cell invasion
    Cekartova, Maria
    Fernando, Romaine I.
    Siriwardhana, Nalin
    Sukhthankar, Mugdha
    de la Parra, Columba
    Woraratphoka, Jirayus
    Malone, Christine
    Stroem, Anders
    Baekd, Seung J.
    Wadef, Paul A.
    Saxton, Arnold M.
    Donnell, Robert M.
    Pestell, Richard G.
    Dharmawardhane, Suranganie
    Wimalasena, Jay
    [J]. EXPERIMENTAL CELL RESEARCH, 2015, 331 (01) : 1 - 10
  • [8] Down regulation of bcl-2 is a potential marker of the efficacy or progestin therapy in the treatment of endometrial hyperplasia
    Amezcua, CA
    Zheng, WX
    Felix, JC
    [J]. LABORATORY INVESTIGATION, 1999, 79 (01) : 112A - 112A
  • [9] ATYPICAL ENDOMETRIAL HYPERPLASIA SIMULATING ADENOCARCINOMA
    NOVAK, E
    RUTLEDGE, F
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1948, 55 (01) : 46 - 63
  • [10] bcl-2 and p53 in endometrial adenocarcinoma
    Taskin, M
    Lallas, TA
    Barber, HRK
    Shevchuk, MM
    [J]. MODERN PATHOLOGY, 1997, 10 (07) : 728 - 734